Protalix Biotherapeutics, Inc. (PLX)
1.975
+0.02
(+0.77%)
USD |
NYAM |
Jun 09, 16:00
1.98
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Research and Development Expense (Quarterly) : 5.426M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Agenus, Inc. | 11.82M |
| Altimmune, Inc. | 16.17M |
| Humacyte, Inc. | 19.46M |
| Amgen, Inc. | 1.719B |
| BioCryst Pharmaceuticals, Inc. | 59.26M |